AstraZeneca plans to nearly double revenue to $80bn by 2030 with 20 new medicines in cancer care, rare diseases.
AstraZeneca plans to nearly double its revenue to $80bn by 2030, as it prepares to launch 20 new medicines in areas like cancer care and rare diseases. Chief Executive Pascal Soriot said many of the new products have the potential to generate more than $5bn a year and "transform millions of lives". The medicines, combined with its existing portfolio, will help AstraZeneca hit its $80bn turnover target, up from $45.8bn last year.
May 21, 2024
55 Articles